The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease

Alzheimer's and Dementia

Volumn 10, Issue 1 SUPPL., 2014, Pages

  Talbot, Konrad ^a   Wang, Hoau Yan ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Glucagon like peptide 1; Hippocampus; Inflammation; Insulin receptor; Insulin receptor substrate 1; Insulin signaling; Liraglutide; Streptozotocin; Type 3 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; INCRETIN; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIRAGLUTIDE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; PROTEIN KINASE B; PROTEIN KINASE C; ROSIGLITAZONE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STREPTOZOCIN; STRESS ACTIVATED PROTEIN KINASE; SULFONYLUREA; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ARTICLE; BRAIN; BRAIN BLOOD FLOW; BRAIN INSULIN RESISTANCE; BRAIN NERVE CELL; CELL FRACTIONATION; CEREBROSPINAL FLUID; DEMENTIA; DISEASE ASSOCIATION; EPISODIC MEMORY; EX VIVO STUDY; GLUCOSE TRANSPORT; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; HUMAN; INSULIN BINDING; INSULIN RESISTANCE; INSULIN RESPONSE; LIPID METABOLISM; MILD COGNITIVE IMPAIRMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ALZHEIMER'S DISEASE; GLUCAGON-LIKE PEPTIDE-1; HIPPOCAMPUS; INFLAMMATION; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE-1; INSULIN SIGNALING; LIRAGLUTIDE; STREPTOZOTOCIN; TYPE 3 DIABETES;

ALZHEIMER DISEASE; ANIMALS; BRAIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN RESISTANCE;

EID: 84897881837     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.12.007     Document Type: Review

References (131)

1. C.R. Jack Jr., M.S. Albert, D.S. Knopman, G.M. McKhann, R.A. Sperling, and M.C. Carrillo et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 257 262
2. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan et al. Toward defining the preclinical stage of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimers Dement 7 2011 280 292
3. Alzheimer's Association 2013 Alzheimer's disease facts and figures Alzheimers Dement 9 2013 208 245
4. C.R. Jack Jr. Alzheimer's disease: new concepts on its neurobiology and the clinical role imaging will play Radiology 263 2012 344 361
5. J.B. Langbaum, A.S. Fleisher, K. Chen, N. Ayutyanont, F. Lopera, and Y.T. Quiroz et al. Ushering in the study and treatment of preclinical Alzheimer disease Nat Rev Neurol 9 2013 371 381
6. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, and N.C. Fox et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup Alzheimers Dement 7 2011 270 279
7. B.C.M. Stephan, S. Hunter, D. Harris, D.J. Llewellyn, M. Siervo, and F.E. Matthews et al. The neuropathological profile of mild cognitive impairment (MCI): a systematic review Mol Psychiatry 17 2012 1056 1076
8. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., and C.H. Kawas et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup Alzheimers Dement 7 2011 263 269
9. C. Reitz, C. Brayne, and R. Mayeux Epidemiology of Alzheimer disease Nat Rev Neurol 7 2011 137 152
10. K. Mullane, and M. Williams Alzheimer's therapeutics: continued clinical failures question the amyloid hypothesis - but what lies beyond? Biochem Pharmacol 85 2013 289 305
11. A. Corbett, J. Pickett, A. Burns, J. Corcoran, S.B. Dunnett, and P. Edison et al. Drug repositioning for Alzheimer's disease Nat Rev Drug Discov 11 2012 833 846
12. M.D. Naylor, J.H. Karlawish, S.E. Arnold, A.S. Khachaturian, Z.S. Khachaturian, and M.-Y. Lee et al. Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit Alzheimers Dement 8 2012 445 452
13. Y. Liu, F. Liu, I. Grundke-Iqbal, K. Iqbal, and C.-X. Gong Deficient brain insulin signaling pathway in Alzheimer's disease and diabetes J Pathol 225 2011 54 62
14. K. Talbot, H.-Y. Wang, H. Kazi, L.-Y. Han, K.P. Bakshi, and A. Stucky et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline J Clin Invest 122 2012 1316 1338
15. S. Hoyer, D. Müller, and K. Plaschke Densensitization of brain insulin receptor. Effect on glucose/energy and related metabolism J Neural Transm Suppl 44 1994 259 268
16. N. Henneberg, and S. Hoyer Desensitization of the neuronal insulin receptor: a new approach in the etiopathogenesis of late-onset sporadic dementia of the Alzheimer type (SDAT)? Arch Gerontol Geriatr 21 1995 63 74
17. E.J. Rivera, A. Goldin, N. Fulmer, R. Tavares, J.R. Wands, and S.M. de la Monte Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine J Alzheimers Dis 8 2005 247 268
18. L. Frölich, D. Blum-Degen, H.-G. Bernstein, S. Engelsberger, J. Humrich, and S. Laufer et al. Brain insulin and insulin receptors in aging and sporadic Alzheimers disease J Neural Transm 105 1998 423 438
19. W.-Q. Zhao, H. Chen, M.J. Quon, and D.L. Alkon Insulin and the insulin receptor in experimental models of learning and memory Eur J Pharmacol 490 2004 71 81
20. M. Salkovic-Petrisic, and S. Hoyer Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach J Neural Transm 114 Suppl. 72 2007 217 233
21. M. Salkovic-Petrisic, A. Knezovic, S. Hoyer, and P. Riederer What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research J Neural Transm 120 2013 233 252
22. P.J. Blackshear, R.A. Nemenoff, and J. Avruch Characteristics of insulin and epidermal growth factor stimulation of receptor autophosphorylation in detergent extracts of rat liver and transplantable rat hepatomas Endocrinology 114 1984 141 152
23. J.M. Amatruda, and A.M. Roncone Normal hepatic insulin receptor autophosphorylation in nonketotic diabetes mellitus Biochem Biophys Res Commun 129 1985 163 170
24. T. Kadowaki, M. Kasuga, Y. Akanuma, O. Ezaki, and F. Takaku Decreased autophosphorylation of the insulin receptor-kinase in streptozotocin-diabetic rats J Biol Chem 259 1984 14208 14216
25. C.F. Burant, M.K. Truetelaar, and M.G. Buse Diabetes-induced functional and structural changes in insulin receptors from rat skeletal muscle J Clin Invest 77 1986 260 270
26. S. Lenzen The mechanisms of alloxan- and streptozotocin-induced diabetes Diabetologia 51 2008 216 226
27. M. Arluison, M. Quignon, P. Nguyen, B. Thorens, C. Leloup, and L. Penicaud Distribution and anatomical localization of the glucose transporter 2 (GLUT2) in the adult rat brain - an immunohistochemical study J Chem Neuroanat 28 2004 117 136
28. T. Kuwabara, M.N. Kagalwala, Y. Onuma, Y. Ito, M. Warashina, and K. Terashima et al. Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb EMBO Mol Med 3 2011 742 754
29. T. Nemoto, F. Toyoshima-Aoyama, T. Yanagita, T. Maruta, H. Fujita, and T. Koshida et al. New insights concerning insulin synthesis and its secretion in rat hippocampus and cerebral cortex: amyloid-β1-42-induced reduction of proinsulin level via glycogen synthase kinase-3β Cell Signal 26 2014 253 259
30. J. Havrankova, J. Roth, and M.J. Borwnstein Concentrations of insulin and of insulin receptors in the brain are independent of peripheral insulin levels, studies of obese and streptozotocin-treated rodents J Clin Invest 64 1979 636 642
31. E. Grünblatt, M. Salkovic-Petrisic, J. Osmanovic, P. Riederer, and S. Hoyer Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein J Neurochem 101 2007 757 770
32. R. Agrawal, E. Tyagi, R. Shukla, and C. Nath Insulin receptor signaling in rat hippocampus: a study in STZ (ICV) induced memory deficit model Eur Neuropsychopharmacol 21 2011 261 273
33. Y. Chen, Z. Liang, J. Blanchard, C.-L. Dai, S. Sun, and M.H. Lee et al. A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse) Mol Neurobiol 47 2013 711 725
34. A. Kraska, M.D. Santin, O. Dorieux, N. Joseph-Mathurin, E. Bourrin, and F. Petit et al. In vivo cross-sectional characterization of cerebral alterations induced by intracerebroventricular administration of streptozotocin PLoS One 7 2012 e4646196
35. S. Rai, P.K. Kamat, C. Nath, and R. Shukla Glial activation and post-synaptic neurotoxicity: the key events in streptozotocin (icv) induced memory impairment in rats Pharmacol Biochem Behav 117C 2013 104 117
36. B. Thorens Brain glucose sensing and neural regulation of insulin and glucagon secretion Diabetes Obes Metab 13 Suppl. 1 2011 82 88
37. E. Steen, B.M. Terry, E.J. Rivera, J.L. Cannon, T.R. Neely, and R. Tavares et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 7 2005 63 80
38. R.J. Griffin, A. Moloney, M. Kelliher, J.A. Johnston, R. Ravid, and P. Dockery et al. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology J Neurochem 93 2005 105 117
39. K. Talbot, L.-Y. Han, J.A. Schneider, R.S. Wilson, D.A. Bennett, and S.E. Arnold Expression of plRS-1 (S312 and S616) is elevated in MCI and AD and correlates with cognitive impairment and neurofibrillary pathology Alzheimers Dement 2 Suppl. 1 2006 S54
40. A.M. Moloney, R.J. Griffin, S. Timmons, R. O'Conner, R. Ravid, and C. O'Neill Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling Neurobiol Aging 31 2010 224 243
41. Q.-L. Ma, F. Yang, E.R. Rosario, O.J. Ubeda, W. Beech, and D.J. Gant et al. β-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by fatty acids and curcumin J Neurosci 29 2009 9078 9089
42. S. Boura-Halfon, and Y. Zick Phosphorylation of IRS proteins, insulin action, and insulin resistance Am J Physiol Endocrinol Metab 296 2009 E581 E591
43. M.A. Abdul-Ghani, and R.A. DeFronzo Pathogenesis of insulin resistance in skeletal muscle J Biomed Biotechnol 2010 2010 476279
44. N.T. Vagelatos, and G.D. Eslick Type 2 diabetes as a risk factor for Alzheimer's disease: the confounders, interactions, and neuropathology associated with this relationship Epidemiol Rev 35 2013 152 160
45. C.M. Taniguchi, B. Emanuelli, and C.R. Kahn Critical nodes in signalling pathways: insights into insulin action Nat Rev Cell Biol 7 2006 85 96
46. P. Dalle Pezze, A.G. Sonntag, A. Thien, M.T. Prentzell, M. Gödel, and S. Fischer et al. A dynamic model of mTOR signaling reveals TSC-independent mTORC2 regulation Sci Signal 5 2012 ra25
47. F. Folli, L. Bonfanti, E. Renard, C.R. Kahn, and A. Merighi Insulin receptor substrate-1 (IRS-1) distribution in the rat central nervous system J Neurosci 14 1994 6412 6422
48. H.-Y. Wang, K. Bakshi, M. Frankfurt, A. Stucky, M. Goberdhan, and S.M. Shah et al. Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A J Neurosci 32 2012 9773 9784
49. A. Espinosa, M. Alegret, S. Valero, G. Vinyes-Junqué, I. Hernández, and A. Mauleón et al. A longitudinal follow-up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved J Alzheimers Dis 34 2013 769 780
50. S. Hoyer Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis J Neural Transm 105 1998 415 422
51. S.M. de la Monte Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease Drugs 72 2012 49 66
52. K. Narasimhan, M. Govindasamy, K. Gauthaman, M.A. Kamal, A.M. Abuzenadeh, and M. Al-Qahtani et al. Diabetes of the brain: computational approaches and interventional strategies CNS Neurol Disord Drug Targets 2014 (in press)
53. Y. Fujisawa, K. Sasaki, and K. Akiyama Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type Biol Psychiatry 30 1991 1219 1228
54. V.V. Shuvaev, I. Laffont, J.-M. Serot, J. Fujii, N. Taniguchi, and G. Siest Increased protein glycation in cerebrospinal fluid of Alzheimer's disease Neurobiol Aging 22 2001 397 402
55. R.N. Kalaria, and S.I. Harik Reduced glucose transporter at the bloodâ brain barrier and in cerebral cortex in Alzheimer disease J Neurochem 53 1989 1083 1088
56. A.D. Mooradian, H.C. Chung, and G.N. Shah GLUT-1 expression in the cerebra of patients with Alzheimer's disease Neurobiol Aging 18 1997 469 474
57. Z. Chen, and C. Zhong Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies Prog Neurobiol 108 2013 21 43
58. R. Ghasemi, A. Haeri, L. Dargahi, Z. Mohamed, and A. Ahmadiani Insulin in the brain: sources, localization and functions Mol Neurobiol 47 2013 145 171
59. 3H]glucose uptake into slices from cerebral cortex elicited by excitatory amino acids Neuroscience 12 1984 385 393
60. F.J. Gil-Bea, M. Solas, A. Solomon, C. Mugueta, B. Winblad, and M. Kivipelto et al. Insulin levels are decreased in the cerebrospinal fluid of women with prodromal Alzheimer's disease J Alzheimers Dis 22 2010 405 413
61. S. Craft, E. Peskind, M.W. Schwartz, G.D. Schellenberg, M. Raskind, and D. Porte Jr. Cerebrospinal fluid and plasma levels in Alzheimer's disease, relationship to severity of dementia and apolipoprotein E genotype Neurology 50 1998 164 168
62. J.A. Molina, F.J. Jiménez-Jiménez, C. Vargas, P. Gómez, F. de Bustos, and C. Gómez-Escalonilla et al. Cerebrospinal fluid levels of insulin in patients with Alzheimer's disease Acta Neurol Scand 106 2002 347 350
63. G.M. Reaven The insulin resistance syndrome: definition and dietary approaches to treatment Annu Rev Nutr 25 2005 391 406
64. S.U. Devaskar, S.J. Giddings, P.A. Rajakumar, L.R. Carnaghi, R.K. Menon, and D.S. Zahm Insulin gene expression and insulin synthesis in mammalian neuronal cells J Biol Chem 269 1994 8445 8454
65. J. Unger, T.H. McNeill, R.T. Moxley III, M. White, A. Moss, and J.N. Livingston Distribution of insulin receptor-like immunoreactivity in the rat forebrain Neuroscience 31 1989 143 157
66. W.A. Banks, J.B. Owen, and M.A. Erickson Insulin in the brain: there and back again Pharmacol Ther 136 2012 82 93
67. D. Le Roth, S.A. Hendricks, M.A. Lesniak, S. Rishi, K.L. Becker, and J. Havrankova et al. Insulin in brain and other extrapancreatic tissues of vertebrates and non-vertebrates Adv Metab Disord 10 1983 303 340
68. S. Craft, B. Cholerton, and L.D. Baker Insulin and Alzheimer's disease: untangling the web J Alzheimers Dis 33 Suppl. 1 2013 S263 S275
69. R. Ghasemi, L. Dargahi, A. Haeri, M. Moosavi, Z. Mohamed, and A. Ahmadiani Brain insulin dysregulation: implications for neurological and neuropsychiatric disorders Mol Neurobiol 47 2013 1045 1065
70. B. Mehdi, and M. Chakrabarty Insulin resistance: an emerging link in Alzheimer's disease Neurol Sci 34 2013 1719 1725
71. C. Hooper, R. Killick, and S. Lovestone The GSK3 hypothesis of Alzheimer's disease J Neurochem 104 2008 1433 1439
72. F.G. De Felice Alzheimer's disease and insulin resistance: translating basic science into clinical applications J Clin Invest 123 2013 531 539
73. L. Ho, S. Yemul, L. Knable, P. Katsel, R. Zhao, and V. Haroutunian et al. Insulin receptor expression and activity in the brains of non-diabetic sporadic Alzheimer's disease cases Int J Alzheimers Dis 2012 2012 321280
74. E. Pham, L. Crews, K. Ubhi, L. Hansen, A. Adame, and A. Cartier et al. Progressive accumulation of amyloid-β oligomers in Alzheimer's disease and in amyloid precursor protein transgeneic mice accompanied by selective alterations in synaptic scaffold proteins FEBS J 277 2010 3051 3067
75. J.E. Straub, and D. Thirumalai Toward a molecular theory of early and late events in monomer to amyloid fibril formation Ann Rev Phys Chem 62 2011 437 463
76. S. Matsumura, K. Shinoda, M. Yamada, S. Yokojima, M. Inoue, and T. Ohnishi et al. Two distinct amyloid β-protein (Aβ) assembly pathways leading to oligomers and fibrils identified by combined fluorescence correlation spectroscopy, morphology, and toxicity analyses J Biol Chem 286 2011 11555 11562
77. M.T. Ferretti, and A.C. Cuello Does a pro-inflammatory process precede Alzheimer's disease cognitive impairment? Curr Alzheimer Res 8 2011 164 174
78. M.T. Heneka, K.O. O'Banion, D. Terwel, and M.P. Kummer Neuroinflammatory processes in Alzheimer's disease J Neural Transm 117 2010 919 947
79. P. Menu, and J.E. Vince The NLRP3 inflammasome in health and disease: the good, the bad and the ugly J Transl Immunol 166 2011 1 15
80. M. Schaars, H. Beckert, and A. Halle Assessing β-amyloid-induced NLRP3 inflammasome activation in primary microglia Methods Mol Biol 1040 2013 1 8
81. M.T. Heneka, M.P. Kummer, A. Stutz, A. Delekate, S. Schwartz, and A. Vieira-Saecker et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice Nature 493 2013 674 678
82. T.R. Bomfim, L. Forny-Germano, L.B. Sathler, J. Brito-Moreira, J.C. Houzel, and H. Decker et al. An antidiabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers J Clin Invest 122 2012 1339 1353
83. M.V. Lourenco, J.R. Clarke, R.L. Frozza, T.R. Bomfim, L. Forny-Germano, and A.F. Batista et al. TNF-α mediates brain IRS-1 inhibition and PKR-dependent memory impairment induced by Alzheimer's-linked amyloid-β oligomers in mice and monkeys Cell Metab 18 2013 831 843
84. L. Ho, W. Qin, P.N. Pompl, Z. Xiang, J. Wang, and Z. Zhao et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease FASEB J 18 2004 902 904
85. A246E mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein Diabetologia 54 2011 2143 2151
86. L.A. Profenno, A.P. Porsteinsson, and S.V. Faraone Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders Biol Psychiatry 67 2010 505 512
87. S. Schenk, M. Saberi, and J.M. Olefsky Insulin sensitivity: modulation by nutrients and inflammation J Clin Invest 118 2008 2992 3002
88. M.S.H. Akash, K. Rehman, and S. Chen Role of inflammatory mechanism in pathogenesis of type 2 diabetes mellitus J Cell Biochem 114 2013 525 531
89. M.A. Erickson, K. Dohi, and W.A. Banks Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier Neuroimmunomodulation 19 2012 121 130
90. C. Tamaki, S. Ohtsuki, and T. Terasaki Insulin facilitates the hepatic clearance of plasma amyloid β-peptide (1-40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes Mol Pharmacol 72 2007 850 855
91. M.A. Marques, J.J. Kulstad, C.E. Savard, P.S. Green, S.P. Lee, and S. Craft et al. Peripheral amyloid-β levels regulate amyloid-β clearance from the central nervous system J Alzheimers Dis 16 2009 325 329
92. 1c and fasting plasma glucose: National Health and Nutrition Examination Surveys 1999-2010 Diabetes Care 36 2013 2286 2293
93. Y.J. Cheng, G. Imperatore, L.S. Geiss, J. Wang, S.H. Saydah, and C.C. Cowie et al. Secular changes in the age-specific prevalence of diabetes among U.S. adults, 1988-2010 Diabetes Care 36 2013 2690 2696
94. R. Estruch, E. Ros, J. Salas-Salvadó, M.-I. Covas, D. Corella, and F. Arós et al. Primary prevention of cardiovascular disease with a Mediterranean diet N Engl J Med 368 2013 1279 1290
95. K. Talbot Brain insulin resistance, diet, and cognitive decline in Alzheimer's disease C.R. Martin, V.R. Preedy, Diet and nutrition in dementia and cognitive decline 2014 Elsevier London
96. S. Balsomo, J.M. Willardson, F. Santos de Santana, J. Prestes, D.C. Balsamo, and D. da Cunha Nascimento et al. Effectiveness of exercise on cognitive impairment and Alzheimer's disease Int J Gen Med 6 2013 387 391
97. B.M. Brown, J.J. Peiffer, and R.N. Martins Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease? Mol Psychiatry 18 2013 864 874
98. V. Solfrizzi, V. Frisardi, D. Seripa, G. Logroscino, B.P. Imbimbo, and G. D'Onofrio et al. Mediterranean diet in predementia and dementia syndromes Curr Alzheimer Res 8 2011 520 542
99. G.M. Cole, Q.-L. Ma, and S.A. Frautschy Omega-3 fatty acids and dementia Prostoglandins Leukot Essent Fatty Acids 81 2009 213 221
100. S. Gillette-Guyonnet, M. Secher, and B. Vellas Nutrition and neurodegeneration: epidemiological evidence and challenges for future research Br J Clin Pharmacol 75 2013 738 755
101. P. Imfeld, M. Bodmer, S.S. Jick, and C.R. Meier Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study J Am Geriatr Soc 60 2012 916 921
102. B.W. Miller, K.C. Willett, and A.R. Desilets Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease Ann Pharmacother 45 2011 1416 1424
103. A.V. Hernandez, A. Usmani, A. Rajamanickam, and A. Moheet Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus Am J Cardiovasc Drugs 11 2011 115 128
104. E. Shemesh, A. Rudich, I. Harman-Boehm, and T. Cukierman-Yaffe Effect of intranasal insulin on cognitive function: a systematic review J Clin Endocrinol Metab 97 2012 366 376
105. J. Freiherr, M. Hallschmid, W.H. Frey II, Y.F. Brünner, C.D. Chapman, and C. Hölscher et al. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence CNS Drugs 27 2013 505 514
106. J.E. Campbell, and D.J. Drucker Pharmacology, physiology, and mechanisms of incretin hormone action Cell Metab 17 2013 819 837
107. I.J. Llewellyn-Smith, F. Reimann, F.M. Gribble, and S. Trapp Preproglucagon neurons project widely to autonomic control areas Neuroscience 180 2011 111 121
108. C. Kappe, L.M. Tracy, C. Patrone, K. Iverfeldt, and A. Sjöholm GLP-1 secretion by microglial cells and decreased CNS expression in obesity J Neuroinflammation 9 2012 276
109. I. Salcedo, D. Tweedie, Y. Li, and N.H. Greig Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders Br J Pharmacol 166 2012 1586 1599
110. A.I. Duarte, E. Candeias, S.C. Correia, R.X. Santos, C. Carvalho, and S. Cardoso et al. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration Bicohim Biophys Acta 1832 2013 527 541
111. K. Hunter, and C. Hölscher Drugs developed to treat diabetes, liraglutide and lixesenatide, cross the blood brain barrier and enhance neurogenesis BMC Neurosci 13 2012 33
112. H. Gao, X. Wang, Z. Zhang, Y. Yang, J. Yang, and X. Li et al. GLP-1 amplifies insulin signaling by upregulation of IRβ, IRS-1, and GLUT4 in 3T3-L1 adipocytes Endocrine 32 2007 90 95
113. L. Li, G. Yang, and Q. Li Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels Diabetes Obes Metab 10 2008 921 930
114. A. Garber, R. Henry, R. Ratner, P.A. Garcia-Hernandez, H. Rodriguez-Pattzi, and I. Olvera-Alvarez et al. Liraglutide versus glimepiride for type 2 diabetes (LEAD-3 Mono): randomized, 52-week, phase III, double-blind, parallel-treatment trial Lancet 373 2009 473 481
115. C.L. Boland, M. DeGeeter, D.S. Nuzum, and M. Tzefos Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors Ann Pharmacother 47 2013 490 505
116. K.R. Peters Liraglutide for the treatment of type 2 diabetes: a clinical update Am J Ther 20 2013 178 188
117. C. Alves, F. Batel-Marques, and A.F. Macedo A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer Diabetes Res Clin Pract 98 2012 271 284
118. A.J. Kastin, and V. Akerstrom Entry of exendin-4 into brain is rapid but may be limited at high doses Int J Obes Rel Disord 27 2003 313 318
119. A. Hamilton, and C. Hölscher Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system NeuroReport 20 2009 1161 1166
120. P.L. McLean, V. Parthsarathy, E. Faivre, and C. Hölscher The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease J Neurosci 31 2011 6587 6594
121. P.L. McLean, and C. Hölscher Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease Neuropharmacology 76 2014 57 67
122. C.M. Long-Smith, S. Manning, P.L. McClean, M.F. Coakley, D.J. O'Halloran, and C. Holscher et al. The diabetes drug liraglutide ameliorates aberrant insulin receptor localization and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease Neuromolecular Med 15 2013 102 114
123. H.-Y. Wang, A. Stucky, J. Kvasic, S.M. Shah, K.P. Bakshi, and P.L. McClean et al. The diabetes drug liraglutide ameliorates insulin resistance in the hippocampal formation of the APP/PS1 model of Alzheimer's disease (AD) Soc Neurosci 2012 Available at: (http://www.abstractsonline.com/Plan/ViewAbstract. aspx?sKey=83790ca3-9647-44bb-ad6c-a188ad342385&cKey=d746ee0b-28c3-40d9-bdb5- ca5996a6b725&mKey=%7b70007181-01C9-4DE9-A0A2-EEBFA14CD9F1%7d). Accessed January 28, 2014.
124. V.L. Villemagne, and C.C. Rowe Long night's journey into the day: amyloid-β imaging in Alzheimer's disease J Alzheimers Dis 33 Suppl. 1 2013 S349 S359
125. M. Koronyo-Hamaoui, Y. Koronyo, A.V. Ljubimov, C.A. Miller, M.K. Ko, and K.L. Black et al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive optical imaging of retinal plaques in a mouse model Neuroimage 54 Suppl. 10 2011 S204 S217
126. C. Hölscher Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection CNS Drugs 26 2012 871 882
127. I. Aviles-Olmos, J. Dickson, Z. Kefalopoulou, A. Djamshidian, P. Ell, and T. Soderlund et al. Exenatide and the treatment of patients with Parkinson's disease J Clin Invest 123 2013 2730 2736
128. D. Bosco, M. Plastino, D. Cristiano, C. Colica, C. Ermio, and M. De Bartolo et al. Dementia is associated with insulin resistance in patients with Parkinson's disease J Neurol Sci 315 2012 39 43
129. S-M Lucas, N.J. Rothwell, and R.M. Gibson The role of inflammation in CNS injury and disease Brit J Pharmacol 147 2006 S232 240
130. B. Finan, T. Ma, N. Ottaway, T.D. Müller, K.M. Habegger, and K.M. Heppner et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans Sci Transl Med 5 2013 209ra151
131. W.-Q. Zhao, P.N. Lacor, H. Chen, M.P. Lambert, M.J. Quon, and G.A. Krafft et al. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric Aβ J Biol Chem 284 2009 18742 18753